Abstract: Resveratrol, a component of a variety of common edible plants, including peanuts and red grapes, is a phytoestrogen. Resveratrol inhibits proliferation of skin epidermal cells (keratinocytes) and stimulates their differentiation. Resveratrol was also found to inhibit melanin production by skin cells and to alleviate skin irritation that may be caused by alpha-hydroxy acids. Resveratrol is useful in improving the appearance of wrinkled, lined, dry, flaky, aged or photodamaged skin and improving skin thickness, elasticity, flexibility, radiance, glow and plumpness.
Type:
Grant
Filed:
June 16, 1998
Date of Patent:
August 7, 2001
Assignee:
Chesebrough-Pond's USA Co., division of Conopco
Inventors:
Robert George Carson, Krupa Patel, Marieann Carlomusto, Carol Annette Bosko, Sreekumar Pillai, Uma Santhanam, Ronni Lynn Weinkauf, Koichi Iwata, Laura Rose Palanker
Abstract: The invention relates to the use of cinnamic acid, or of at least one of its derivatives, in a cosmetic composition as a firming agent for the skin and/or mucous membranes.
The invention also relates to a firming composition comprising cinnamic acid or at least one of its derivatives.
Type:
Grant
Filed:
December 21, 1998
Date of Patent:
July 31, 2001
Assignee:
Societe L'Oreal S.A.
Inventors:
Lionel Breton, Florence Girerd, Béatrice Renault
Abstract: A method of hydrating nasal airway surfaces in a subject in need of such treatment comprises topically applying a sodium channel blocker to a nasal airway surface of the subject in an amount effective to inhibit the reabsorption of water by the surface. The channel blocker may be a pyrazinoylguanidine sodium channel blocker, such as benzamil, phenamil, amiloride, or a pharmaceutically acceptable salts thereof. The method may further comprise the step of topically applying a P2Y2 receptor agonist to a nasal airway surface of the subject in an amount effective to stimulate chloride secretion by the nasal airway surface. In a preferred embodiment, the sodium channel blocker is a covalent conjugate of a pyrazinoylguanidine sodium channel blocker and a non-absorbable carrier moiety (e.g., albumin, polyethylene glycol). Such compounds may also be administered to other mucosal surfaces where it is desired to inhibit the reabsorption of water.
Type:
Grant
Filed:
October 20, 1999
Date of Patent:
July 24, 2001
Assignee:
The University of North Carolina at Chapel Hill
Abstract: The invention relates to the use of cinnamic acid, or of at least one of its derivatives, in a cosmetic composition as an agent for promoting the synthesis of the skin's total lipids.
The invention also relates to a cosmetic composition comprising an effective amount of cinnamic acid or of at least one of its derivatives.
Type:
Grant
Filed:
December 21, 1998
Date of Patent:
July 24, 2001
Assignee:
Societe l'Oreal S.A.
Inventors:
Lionel Breton, Florence Girerd, Béatrice Renault
Abstract: A method for making a biocompatible medical article, and preferably, a blood compatible medical article, through the use of a copolymer coating. The copolymer coating is synthesized using methacrylate or acrylate monomers with a functional group (primary amino group) for subsequent attachment of heparin. Synthesis of the copolymer coating is carried out using the proper proportion of hydrophobic monomer/hydrophilic monomer/functional monomer in order to optimize the solubility of the copolymer in alcohol, its insolubility in water (before and after heparin coupling), the heparin coupling efficacy and heparin bioactivity. Once the copolymer coating is fashioned, a medical article is coated with it. The coating is thereafter dried and heparin attached. In such a manner the present invention provides for a method for making a biocompatible medical article, and preferably, a blood compatible medical article.
Type:
Grant
Filed:
April 3, 1998
Date of Patent:
July 10, 2001
Assignee:
Medtronic Inc
Inventors:
Edouard Koulik, Larik Vincent, Patrick Cahalan, Eric Fogt, Kazuhiko Ishihara, Nobuo Nakabayashi
Abstract: The present invention comprises chewable, soft gelatin capsules having a sheath formed of a mixture of a low bloom and a medium bloom gelatins, a plasticizer, water, and preferably a moisture retention agent to enhance the machinability and integrity of the sheath composition; and a fill of an active material in a carrier liquid.
Abstract: A medicament carrier (10) having a first and a second spaced apart screen (12, 14) each of which has surfaces (12B, 14B) defining a plurality of interstices (12A, 14A). The carrier (10) contains powdered agglomerated medicament particles (SM) loaded onto the first screen surface (12B) such that the interstices (12A) of the first screen (12) are at least partially open and free of the agglomerated medicament particles (SM). When an air stream is provided to the carrier to entrain the agglomerated powdered medicament particles (SM) and move them from the first screen (12) through the interstices (14A) of the second screen (14), the agglomerated powdered medicament particles (SM) are sheared by air flow gradients created by the first and second screens (12, 14) and by contact with the surface (14B) of the second screen (14) to create particles of respirable particle size range. The carrier (10) can be used in a dry powder inhalator device.
Type:
Grant
Filed:
January 28, 1999
Date of Patent:
June 12, 2001
Assignee:
Glaxo Wellcome Inc.
Inventors:
Michiel Mary Van Oort, Mark Joseph Sacchetti
Abstract: Methods and formulations for making extended release bupropion hydrochloride tablets using direct compression, and tablets formed thereby, are provided which combine bupropion hydrochloride, binders such as polyethylene oxide or hydroxypropyl cellulose, a filler such as lactose, glidants and lubricants under low shear conditions to form hard, chip-resistant tablets which exhibit improved cohesiveness and are easily and reproducibly formed without adhering to the compression punches and dies.
Abstract: A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal C8 to C22 alkyl sulphate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. The amount of each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt. % of the formulation.
Abstract: A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an lkali metal C8 to C22 alkyl sulphate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. The amount of each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt. % of the formulation.
Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.
Type:
Grant
Filed:
May 10, 1999
Date of Patent:
April 24, 2001
Assignee:
Glaxo Group Limited
Inventors:
Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
Abstract: The present invention relates to antipruritic cosmetic and/or pharmaceutical compositions for use on human or animal skin, comprising one or more mild local anesthetics, one or more astringents and/or, if appropriate, a substance having an antiinflammatory action.
Abstract: A topical spreadable composition comprising 5-aminosalicylic acid (5-ASA) as active and monoolein is provided for treatment ulcers, inflammation and lesions of the oral cavity. The composition is spread over and adheres to the lesion, and is preferably prepared in a water free state. Examples of indications that can be treated are oral Crohn's Disease, apthous ulcers, orofacial granulomatosis, oral ulcers associated with Behet's disease and oral lichen planus.
Abstract: Gelatin-free capsule for use in oral administration of medicines, cosmetic or bath applications, or dietary supplements can be prepared from compositions comprising
a) 8-50% by weight of water-dispersible or water-soluble plasticizer,
b) 0.5 to 12% by weight &kgr;-carrageenan,
c) 0 to 60% dextrins, and
d) 1% to 95% by weight water,
with the &kgr;-carrageenan comprising at least 50% by weight of all gums forming or contributing to formation of thermoreversible gels in the composition. A capsule for oral administration or cosmetic application may comprise a fill material to be administered to a patient or subject and a capsule, the capsule comprising an aqueous based film comprising
a) water-dispersible or water-soluble plasticizer, and
b) carrageenan,
with the carrageenan comprising at least 50% or 75% by weight of &kgr;-carrageenan, and the carrageenan comprising at least 50% or 75% by weight of all gums which form or contribute to the formation of thermoreversible gels.
Abstract: This invention involves skin cleaning products and tapes for removing keratotic plugs, dirt and other debris found on the skin and in skin pores and comprising a starch based remoistenable adhesive composition wherein the starch has from about 0 to 70% by weight amylose content and is converted to from about 30 WF to 20 DE.
Type:
Grant
Filed:
September 14, 1998
Date of Patent:
March 27, 2001
Assignee:
National Starch and Chemical Investment Holding
Corporation
Inventors:
Doreen L. Howard, Frank A. Nowak, Jr., Daniel B. Solarek, James L. Eden, Gary T. Martino
Abstract: The present invention relates to topical compositions comprising a collagen enhancing effective amount of a whey protein, vitamin A, vitamin E and vitamin C in combination with each other. Vitamin E and vitamin C components are present in specific ranges based on their inverse effect in boosting collagen synthesis. The compositions can enhance the production of collagen in skin and improve the resiliency of the skin. The increased production of collagen using the compositions of the present invention restores proteins and vitamins to the skin and helps alleviate some of the effects of aging and photoaging of skin. The present invention also includes methods of applying the compositions to the skin.
Type:
Grant
Filed:
November 10, 1998
Date of Patent:
March 20, 2001
Assignee:
Color Access, Inc.
Inventors:
Donald F. Collins, Thomas Mammone, Kenneth D. Marenus
Abstract: An antiflatulent composition is disclosed which comprises a polysaccharide and a preservative. The composition is useful to control gas formation at the site of generation of flatulence.
Abstract: Biodegradable delivery systems of physiologically, pharmacologically and biologically active substance(s) (BAS) are provided. These systems are obtained by incorporating the BAS into a blend of biodegradable polymers and plasticizers using a novel solvent evaporation method. This method involves dissolving the biodegradable polymer or copolymer and a plasticizer into a volatile solvent. The BAS may then be added to this mixture. The volatile solvent is removed using vacuum or at an elevated temperature or using a combination of both vacuum and elevated temperature. The resultant mixture is a BAS-loaded formulation which when injected, implanted or applied in vivo in an animal or human, provides controlled release of the BAS over the desired period of time. Alternatively, a blank formulation may be first prepared by the aforementioned methodology without incorporating the BAS in the formulation.
Abstract: The present invention relates to a stable gel mixture, having a substantially uniform appearance, which stable gel mixture comprises at least one oleogel and of at least one aqueous gel, the oleogel comprising at least one oily agent gelled with at least one cellulose polymer. The present invention also relates to a pharmaceutical composition comprising this gel, to the use of this pharmaceutical composition as a reservoir for active ingredients in a transdermal release system, as well as to a cosmetic composition comprising this gel. This gel has remarkable stability and a fresh and pleasant feel.